Transdermal fentanyl versussustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life

Ahmedzai, Sam H; Brooks, David J.

doi:10.1016/s0885-3924(97)00082-1

Cited by 454 publications

(267 citation statements)

References 9 publications

Supporting

Mentioning

243

Contrasting

Unclassified

Order By: Relevance

“…However, in patients without diarrhea, the antisecretory eff ect of opioids combines with their antipropulsive action to cause constipation. Besides its primary symptoms (hard dry stool, bloating, straining, infrequent and incomplete defecation), opioid-induced constipation may give rise to secondary symptoms including gastroesophageal refl ux, nausea and vomiting, anorexia, abdominal distention, and abdominal pain was associated with acceptable pain relief with signifi cant less constipation than morphine ( 58 ). In noncancer pain, a randomized crossover trial conducted in 256 patients compared transdermal fentanyl with sustained-release oral morphine ( 59 ).…”

Section: Effect Of Exogenous Opioids On the Gastrointestinal Tractmentioning

confidence: 99%

Pharmacology of Opioids and their Effects on Gastrointestinal Function

Holzer¹

2014

Am J Gastroenterol Suppl

View full text Add to dashboard Cite

Opioids are perhaps the most effi cacious analgesic agents available to the clinician in everyday clinical practice. While providing highly effective pain relief, the therapeutic activity of opioids is compromised by gastrointestinal adverse events related to their interaction with the opioid signaling system of the gut, a complex network of peptides and receptors with opioid-like properties that helps to coordinate gastrointestinal motility and secretion. The effects of opioids on the gut are modulated by genetic polymorphisms in opioid receptors, downstream signaling pathways, and enzymes involved in the metabolism of these opioid analgesics. Here, we focus on the physiology of endogenous opioids and their receptors with particular reference to their effects on gastrointestinal function, the pharmacology of opioid drugs, and molecular and genetic factors that drive the activity of these powerful agents.

show abstract

Section: Effect Of Exogenous Opioids On the Gastrointestinal Tractmentioning

confidence: 99%

Pharmacology of Opioids and their Effects on Gastrointestinal Function

Holzer¹

2014

Am J Gastroenterol Suppl

View full text Add to dashboard Cite

show abstract

“…The possibility of opioid switch in the treatment of OIBD should be considered usually rotating codeine to tramadol and morphine to transdermal fentanyl. However, in contrast to clinical studies [10,11], observational surveys do not provide evidence for advantages of transdermal fentanyl over other opioid analgesics with respect to bowel function [12,13].…”

Section: Treatment Of Opioid-induced Bowel Dysfunctionmentioning

confidence: 99%

Are we able to Manage Effectively Opioid-Induced Bowel Dysfunction?

Leppert¹

2012

J Autacoids

View full text Add to dashboard Cite

“…Four controlled studies, however, found that transdermal fentanyl was associated with less frequent laxative use compared with morphine [19][20][21][22]. Tapentadol is a novel μ-opioid agonist that also inhibits norepinephrine, which is believed to augment its analgesic activity [23].…”

Section: Novel Opioids With Less Constipationmentioning

confidence: 99%

Opioid-induced bowel dysfunction

Chang¹,

Lembo

2008

Curr Treat Options Gastro

View full text Add to dashboard Cite

Opioid-induced bowel dysfunction (OIBD) is a potentially debilitating side effect of chronic opioid use. It refers to a collection of primarily gastrointestinal motility disorders induced by opioids, of which opioid-induced constipation (OIC) is the most common. Management of OIBD is difficult, and affected patients will often limit their opioid intake at the expense of experiencing more pain, to reduce the negative impact of OIBD on their quality of life. Effective pharmacologic therapy for OIC is considered an unmet need and several agents have recently been given priority review and approval for OIC. Furthermore, multiple agents currently in development show promise in treating OIC without significant impact on analgesia or precipitation of withdrawal symptoms. The approval and availability of such medications would represent a significant improvement in the management of OIC and OIBD in patients with chronic pain.

show abstract

Transdermal fentanyl versussustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life

Cited by 454 publications

References 9 publications

Pharmacology of Opioids and their Effects on Gastrointestinal Function

Pharmacology of Opioids and their Effects on Gastrointestinal Function

Are we able to Manage Effectively Opioid-Induced Bowel Dysfunction?

Opioid-induced bowel dysfunction

Contact Info

Product

Resources

About